AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28110207 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Program (10 min warm-up, 20 min rhythmic exercises, 10 min cool-down, 30 min free walking, 4 days a week for 10 weeks)
Number of subjects: 80
Study 28110207 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Number of subjects: 80
Study 28110207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 26442396 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 32
Study 26442396 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 32
Study 23801461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sodium hyaluronate
Number of subjects: 78
Study 23801461 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 78
Study 21209236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg (TAD) alone
Number of subjects: 17
Study 21209236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg (TAD) with tipranavir/ritonavir (TPV/r) 500/200 mg
Number of subjects: 17
Study 21209236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg (TAD) with steady-state TPV/r
Number of subjects: 17
Study 20048350 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational programme (8 sessions over 4 weeks)
Number of subjects: 116
Study 17291169 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention
Number of subjects: 337
Study 17291169 — intervention group
Group type: COMPARATOR
Intervention: Generic intervention
Number of subjects: 337
Study 17291169 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 337
Study 15098526 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of ondansetron
Number of subjects: 0
Study 15098526 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg of dolasetron
Number of subjects: 0
Study 11136177 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV carriers (n = 72)
Number of subjects: 195
Study 11136177 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV negative (n = 68)
Number of subjects: 195
Study 11136177 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 123)
Number of subjects: 195
Study 11136177 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects (HBV carriers and HBV negative)
Number of subjects: 195
Study 9519171 — intervention group
Group type: EXPERIMENTAL
Intervention: MXL capsules (once-daily morphine preparation)
Number of subjects: 85
Study 9519171 — intervention group
Group type: COMPARATOR
Intervention: MST Continus tablets (twice-daily morphine preparation)
Number of subjects: 85
Study 8317754 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (approximately 40 degrees C)
Number of subjects: 99
Study 8317754 — intervention group
Group type: COMPARATOR
Intervention: Circulating-water mattresses at 40 degrees C
Number of subjects: 99
Study 2872826 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 3
Study 2872826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 30858019 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization methods (8 different methods used)
Number of subjects: 3813
Study 30858019 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-normality of baseline variables
Number of subjects: 3813
Study 30858019 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength of correlation of baseline variables
Number of subjects: 3813
Study 30858019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rounded summary statistics
Number of subjects: 3813
Study 27862179 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine 10 mg
Number of subjects: 16
Study 27862179 — intervention group
Group type: EXPERIMENTAL
Intervention: phenytoin 300 mg
Number of subjects: 16
Study 27862179 — intervention group
Group type: EXPERIMENTAL
Intervention: pregabalin 300 mg
Number of subjects: 16
Study 27862179 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 3 μg kg-1
Number of subjects: 16
Study 27862179 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen 600 mg
Number of subjects: 16
Study 27862179 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 25216597 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (EPT+) in normotensive women
Number of subjects: 100
Study 25216597 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day) in hypertensive women
Number of subjects: 100
Study 25216597 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg/day) in hypertensive women
Number of subjects: 100
Study 25216597 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (EPT+) with Hydrochlorothiazide in hypertensive women
Number of subjects: 100
Study 25216597 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (EPT+) with Perindopril in hypertensive women
Number of subjects: 100
Study 24334578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches over semipermeable membrane dressings (SMD)
Number of subjects: 28
Study 24334578 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patches without semipermeable membrane dressings (SMD)
Number of subjects: 28
Study 22180403 — intervention group
Group type: EXPERIMENTAL
Intervention: HE4 as a serum marker
Number of subjects: 0
Study 22180403 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125 and HE4 screening
Number of subjects: 0
Study 18083994 — intervention group
Group type: EXPERIMENTAL
Intervention: Preformed tubes
Number of subjects: 92
Study 18083994 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced tubes
Number of subjects: 92
Study 18083994 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermosoftened preformed tubes
Number of subjects: 92
Study 18083994 — intervention group
Group type: COMPARATOR
Intervention: Upper pathway tubes
Number of subjects: 92
Study 16249215 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2 every 3 weeks x 4 cycles with concurrent carboplatin AUC 6 every 3 weeks x 4 cycles
Number of subjects: 161
Study 16249215 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 75 mg/m2/week x 12 with concurrent carboplatin AUC 6 every 3 weeks x 4 cycles
Number of subjects: 161
Study 12548250 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline/rifampin impregnated catheters
Number of subjects: 0
Study 12548250 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine/silver sulfadiazine impregnated catheters
Number of subjects: 0
Study 11101062 — intervention group
Group type: EXPERIMENTAL
Intervention: scIL-2 therapy plus antiretroviral therapy
Number of subjects: 72
Study 11101062 — intervention group
Group type: COMPARATOR
Intervention: antiretroviral therapy alone (control group)
Number of subjects: 72
Study 8793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosections
Number of subjects: 0
Study 8793221 — intervention group
Group type: COMPARATOR
Intervention: Dissection
Number of subjects: 0
Study 1474180 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) monotherapy
Number of subjects: 39
Study 6361793 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 75
Study 6361793 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 75
Study 6361793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31324597 — intervention group
Group type: EXPERIMENTAL
Intervention: iBASIS-VIPP
Number of subjects: 103
Study 31324597 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 103
Study 30345905 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 521
Study 30345905 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 521
Study 30345905 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant (among patients with sensitivity to previous endocrine therapy)
Number of subjects: 521
Study 30345905 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (among patients with sensitivity to previous endocrine therapy)
Number of subjects: 521
Study 26095256 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy with surgery delayed 4-8 weeks (SRT-delay)
Number of subjects: 462
Study 26095256 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy with immediate surgery (SRT)
Number of subjects: 462
Study 23893421 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of a 'psychooncological statement' (PO‐statement) in the discharge summary
Number of subjects: 1416
Study 23893421 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge summary with PO‐statement
Number of subjects: 1416
Study 23893421 — intervention group
Group type: COMPARATOR
Intervention: Control group (discharge summary without PO‐statement)
Number of subjects: 1416
Study 21745388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (2 times per week for 12 sessions over 6 weeks)
Number of subjects: 80
Study 21745388 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no acupuncture treatment for the first 6 weeks)
Number of subjects: 80
Study 19189783 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 205
Study 19189783 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 205
Study 17114544 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time single-shot fast spin-echo (RT SSFSE) imaging
Number of subjects: 69
Study 17114544 — intervention group
Group type: COMPARATOR
Intervention: Standard single-shot fast spin-echo (SSFSE) imaging
Number of subjects: 69
Study 15623608 — intervention group
Group type: EXPERIMENTAL
Intervention: Repifermin 25 microg/kg
Number of subjects: 42
Study 15623608 — intervention group
Group type: EXPERIMENTAL
Intervention: Repifermin 50 microg/kg
Number of subjects: 42
Study 15623608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11740974 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha) 3-6 MUI s.c. three/six times a week for 6 months
Number of subjects: 14
Study 8233298 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin (400 mg/m2 day 1) and 5-fluorouracil (1 g/m2 days 1-5) followed by locoregional treatment (LRT)
Number of subjects: 324
Study 8233298 — intervention group
Group type: COMPARATOR
Intervention: Locoregional treatment (LRT) alone
Number of subjects: 324
Study 2891370 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine orally alone
Number of subjects: 17
Study 2891370 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine orally with antacid
Number of subjects: 17
Study 2891370 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine orally with a standard breakfast
Number of subjects: 17
Study 31972380 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 58
Study 31972380 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 28631456 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine group (20 mL of bupivacaine hydrochloride 0.375% + 12 mg adenosine in 2 mL of saline 0.9%)
Number of subjects: 0
Study 28631456 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium group (20 mL of bupivacaine hydrochloride 0.375% + 500 mg magnesium sulphate in 2 mL saline 0.9%)
Number of subjects: 0
Study 28631456 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 mL of bupivacaine hydrochloride 0.375% + 2 mL saline 0.9%)
Number of subjects: 0
Study 27236075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weeks positive body exposure (n = 15)
Number of subjects: 28
Study 27236075 — intervention group
Group type: COMPARATOR
Intervention: No-treatment condition (n = 13)
Number of subjects: 28
Study 25688357 — intervention group
Group type: EXPERIMENTAL
Intervention: AJG522
Number of subjects: 0
Study 25688357 — intervention group
Group type: COMPARATOR
Intervention: PEG+E
Number of subjects: 0
Study 23719554 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg FA/d
Number of subjects: 119
Study 23719554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 20620713 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave Reflection Index (WRI)
Number of subjects: 259
Study 20620713 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Augmentation Index (cAI(x))
Number of subjects: 259
Study 20620713 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak backward to peak forward pressure ratio (P(b)/P(f))
Number of subjects: 259
Study 20620713 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased left ventricular mass index and elevated B-type natriuretic peptide
Number of subjects: 259
Study 19138244 — intervention group
Group type: EXPERIMENTAL
Intervention: Florajen (probiotic)
Number of subjects: 40
Study 19138244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16614274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil added to existing antianginal treatment
Number of subjects: 0
Study 12538428 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 169
Study 12538428 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 169
Study 10649211 — intervention group
Group type: COMPARATOR
Intervention: Investigational drug (placebo-controlled)
Number of subjects: 350
Study 10649211 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-ventricle repair
Number of subjects: 350
Study 10649211 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ventricle palliation
Number of subjects: 350
Study 10649211 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative risk model
Number of subjects: 350
Study 10649211 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative risk model (duration of deep hypothermic circulatory arrest)
Number of subjects: 350
Study 9175213 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic pouch anastomosis
Number of subjects: 45
Study 9175213 — intervention group
Group type: COMPARATOR
Intervention: Straight anastomosis
Number of subjects: 45
Study 8402740 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem 60 mg tid
Number of subjects: 10
Study 8402740 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem SR 120 mg bid
Number of subjects: 10
Study 3079940 — intervention group
Group type: EXPERIMENTAL
Intervention: PY 108-068 (75 mg/day)
Number of subjects: 12
Study 3079940 — intervention group
Group type: EXPERIMENTAL
Intervention: PY 108-068 (150 mg/day)
Number of subjects: 12
Study 3079940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29111391 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with scaling and root planing (SRP)
Number of subjects: 53
Study 29111391 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 53
Study 29111391 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with SRP
Number of subjects: 53
Study 26593105 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of care
Number of subjects: 442
Study 26593105 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 442
Study 25035208 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 135
Study 21924220 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert feedback after applying an emotionally activating stimulus
Number of subjects: 218
Study 21924220 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer feedback after applying an emotionally activating stimulus
Number of subjects: 218
Study 21924220 — intervention group
Group type: COMPARATOR
Intervention: Standard without feedback
Number of subjects: 218
Study 21924220 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert feedback
Number of subjects: 218
Study 21924220 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 218
Study 20117307 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuFlex implants
Number of subjects: 33
Study 20117307 — intervention group
Group type: COMPARATOR
Intervention: Swanson implants
Number of subjects: 33
Study 20117307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 18180637 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine
Number of subjects: 35
Study 18180637 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% amitriptyline
Number of subjects: 35
Study 18180637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15917384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim (6 mug/kg/day for 56 days)
Number of subjects: 124
Study 15917384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 12526955 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (12.5, 25, and 50 microg/kg/min for Low; 25, 50, and 100 microg/kg/min for High)
Number of subjects: 10
Study 12526955 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusions only)
Number of subjects: 10
Study 10563070 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg once daily
Number of subjects: 0
Study 10563070 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 0
Study 8730416 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dialysate (CaD) of 1.75 mmol/l
Number of subjects: 18
Study 8730416 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dialysate (CaD) of 1.25 mmol/l
Number of subjects: 18
Study 8730416 — intervention group
Group type: COMPARATOR
Intervention: Standard calcium dialysate (SCaD)
Number of subjects: 18
Study 8730416 — intervention group
Group type: COMPARATOR
Intervention: Low calcium dialysate (LCaD)
Number of subjects: 18
Study 1407617 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic pretreatment of heart valve prostheses
Number of subjects: 1262
Study 1407617 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 1262
Study 3930246 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 0.45 mg kg‐1 day‐1
Number of subjects: 15
Study 3930246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30543172 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilla seed oil
Number of subjects: 182
Study 30543172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 29596213 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 125
Study 29596213 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 125
Study 27388373 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive basic care management (PBCM)
Number of subjects: 99
Study 27388373 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 99
Study 27388373 — intervention group
Group type: EXPERIMENTAL
Intervention: PBCM
Number of subjects: 99
Study 24612027 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial dermabrasion (16 weekly sessions)
Number of subjects: 32
Study 24612027 — intervention group
Group type: COMPARATOR
Intervention: Topical tretinoin cream (0.05% daily)
Number of subjects: 32
Study 22074015 — intervention group
Group type: EXPERIMENTAL
Intervention: HiRes 120
Number of subjects: 65
Study 22074015 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmony processor
Number of subjects: 65
Study 22074015 — intervention group
Group type: COMPARATOR
Intervention: HiRes
Number of subjects: 65
Study 19854610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DAB) 110 mg
Number of subjects: 512
Study 19854610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DAB) 150 mg
Number of subjects: 512
Study 19854610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DAB) 220 mg
Number of subjects: 512
Study 19854610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 17913961 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha -308 G/A allele frequencies in women with pregnancy complications (cases)
Number of subjects: 1652
Study 17913961 — intervention group
Group type: COMPARATOR
Intervention: TNF-alpha -308 G/A allele frequencies in women without pregnancy complications (controls)
Number of subjects: 1652
Study 17913961 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha -308 G/A genotype distributions in women with pregnancy complications (cases)
Number of subjects: 1652
Study 17913961 — intervention group
Group type: COMPARATOR
Intervention: TNF-alpha -308 G/A genotype distributions in women without pregnancy complications (controls)
Number of subjects: 1652
Study 17913961 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TNF-alpha -308 G/A genotype distributions between cases and controls
Number of subjects: 1652
Study 17913961 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TNF-alpha -308 G/A allele frequencies between cases and controls
Number of subjects: 1652
Study 15911462 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc as an adjuvant to malaria therapy
Number of subjects: 0
Study 15911462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12126383 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide dry ice sticks (CO2)
Number of subjects: 15
Study 12126383 — intervention group
Group type: COMPARATOR
Intervention: Refrigerant spray (RS)
Number of subjects: 15
Study 10726107 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial lipemia (200 ml of 30% cream) in IHD patients
Number of subjects: 30
Study 10726107 — intervention group
Group type: COMPARATOR
Intervention: Postprandial lipemia (200 ml of 30% cream) in healthy controls
Number of subjects: 30
Study 7862217 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard procedure (SP) for determining hypertension as described by the DCGP
Number of subjects: 94
Study 7862217 — intervention group
Group type: EXPERIMENTAL
Intervention: First blood pressure measurement high (diastolic pressure 105-115 mmHg)
Number of subjects: 94